Natalizumab in the treatment of patients with multiple sclerosis: First experience

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 465-473

  Mareckova, Helena ^a   Havrdova, Eva ^a   Krasulova, Eva ^a   Vankova, Zdenka ^a   Koberová, Michaela ^a   Šterzl, Ivan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

CCR5; Chemokine receptor; Flow cytometry; Multiple sclerosis; Natalizumab

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; NATALIZUMAB; PLACEBO;

ADULT; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INFLAMMATION; LYMPHOCYTE; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; STATISTICAL SIGNIFICANCE;

EID: 35748979436     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.049     Document Type: Conference Paper

References (14)

1. BITSCH, A. et al. 2000. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123: 1461-1483.
2. OPPERMANN, M. 2004. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell. Signal. 16: 1201-1210.
3. KRAKAUER, M. et al. 2006. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand. J. Immunol. 64: 155-163.
4. RICE, G.P.A. et al. 2005. Anti-α4 integrin therapy for multiple sclerosis. Mechanisms and rationale. Neurology 64: 1336-1342.
5. POLMAN, C.H. et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354: 899-910.
6. STUVE, O. et al. 2006. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59: 743-747.
7. RUDICK, R.A. et al. 2006. Natalizumab plus interferon beta-1 α for relapsing multiple sclerosis. N. Engl. J. Med. 354: 911-923.
8. STUVE, O. et al. 2006. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. 63: 1383-1387.
9. LIM, J.K. et al. 2006. CCR5: no longer a "good for nothing" gene - chemokine control of West Nile virus infection. Trends Immunol. 27: 308-312.
10. KUUSISTO, E.I. 2005. Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation. Acta Neurol. Scand. 113: 163-166.
11. MISU, T. et al. 2001. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signalling. J. Neuroimmun. 114: 207-212.
12. ALLIE, R. et al. 2005. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch. Neurol. 62: 889-894.
13. UBOGU, E.E. et al. 2007. CCR5 expression on monocytes and T cells: Modulation by transmigration across the blood-brain barrier in vitro. Cell. Immunol. 243: 19-29.
14. CALLAHAN, M.K. 2004. CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J. Neuroimmunol. 153:150-157.